EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Risk of Serious Infections in Patients Treated With Biologic or Targeted‐synthetic Disease Modifying Antirheumatic Drugs in Qatar

Sreethish Sasi iD, Hamad Abdel Hadi, Masautso Chaponda, Reem El Ajez iD, Mohamed Ataelmanan, Sief Khasawneh, Hind Saqallah, Maisa Ali, Nabeel Abdulla, Javed Iqbal iD, Ali S Omrani, Muna Al Maslamani und 1 weitere

Immunity, Inflammation and Disease · 2025

DOI: 10.1002/iid3.70195 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immunity, Inflammation and Disease, 2025. Verfasst von Sreethish Sasi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Communicable Diseases Center, Infectious Diseases Division, Hamad Medical Corporation, Doha, Qatar. Hauptthemen laut MEDLINE: Antirheumatic Agents, Opportunistic Infections, Biological Products. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This article was funded by Qatar National Library under QNL Open Access Program..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Biologic and targeted‐synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs), are pivotal in the management of autoimmune‐inflammatory disorders, acting by suppressing pathological immune activation. Because of associated immune dysfunction, opportunistic or serious infections (SIs), and latent disease reactivation is frequently reported. This study aimed to investigate the epidemiology, risk factors, and outcomes of SIs in patients treated with b/tsDMARDs in Qatar.

Methods

A retrospective cohort study was conducted at Hamad Medical Corporation, including all the patients treated with one of 10 b/tsDMARDs, between January 2017 and July 2021. Besides descriptive statistics, the Chi‐square test and Kaplan–Meyer survival analysis were used for statistical analysis.

Results

Out of 1092 patients, 86 (7.9%) had SIs, with an incidence rate of 39.4 per 1000 patient years. Mean duration of onset was 10.8 months post‐initiation of therapy. Younger age groups (18–52 years) were predominantly affected. A significant association was observed between the primary diagnosis (rheumatological followed by gastrointestinal, neurological, and dermatological disorders) and the occurrence of SIs ( χ ² = 9.512, p < 0.050). Adalimumab and infliximab had a higher risk of SIs compared to other b/tsDMARDs. There was no significant difference between TNF‐inhibitors and others. Ocrelizumab was significantly associated with incidence of COVID‐19 SIs ( χ ² = 16.84, p = 0.0000408), and etanercept with Staphylococcus aureus SIs ( χ ² = 17.51, p = 0.0000285). Predominant infection sites were skin–soft tissue and respiratory tract. Most of the SIs were secondary to either bacteria (43%) or viruses (17.4%). The mean duration of hospitalization was 9 days, and 7% of patients required critical care, with no recorded 90‐day mortality.

Conclusions

Patients with inflammatory conditions managed with b/tsDMARDs are at significant risk of SIs, which necessitate appropriate patient selection weighing benefits and risks, as well as careful long‐term management that include patient education and relevant preventive therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antirheumatic AgentsOpportunistic InfectionsBiological ProductsHumansAdultMaleMiddle AgedQatarFemaleRetrospective StudiesAdolescentYoung AdultRisk FactorsIncidenceAged

Stichwörter der Autor:innen

DMARDTNF‐alpha inhibitorbiologicimmunocompromisedtofacitinib

Substanzen

Antirheumatic AgentsBiological Products

Autor:innen und Institutionen

  • Department of Medicine, Communicable Diseases Center, Infectious Diseases Division, Hamad Medical Corporation, Doha, Qatar.
  • Department of Medicine, Infectious Diseases Division, Al-Wakra Hospital, Hamad Medical Corporation, Doha, Qatar.
  • Department of Pharmacy, Hamad Medical Corporation, Doha, Qatar.
  • Department of Internal Medicine, Hamad Medical Corporation, Doha, Qatar.
  • Department of Internal Medicine, Rheumatology Division, Hamad Medical Corporation, Doha, Qatar.
  • Department of Nursing, Communicable Diseases Center, Hamad Medical Corporation, Doha, Qatar.

ORCID-Profile: Sreethish Sasi, Reem El Ajez, Javed Iqbal

Förderung

  • This article was funded by Qatar National Library under QNL Open Access Program.

Zitieren

APA

Sasi, S., Hadi, H. A., Chaponda, M., El Ajez, R., Ataelmanan, M., Khasawneh, S., Saqallah, H., Ali, M., Abdulla, N., Iqbal, J., Omrani, A. S., Al Maslamani, M., & Al-Khal, A. (2025). Risk of Serious Infections in Patients Treated With Biologic or Targeted‐synthetic Disease Modifying Antirheumatic Drugs in Qatar. Immunity, Inflammation and Disease. https://doi.org/10.1002/iid3.70195

Vancouver

Sasi S, Hadi HA, Chaponda M, El Ajez R, Ataelmanan M, Khasawneh S, et al. Risk of Serious Infections in Patients Treated With Biologic or Targeted‐synthetic Disease Modifying Antirheumatic Drugs in Qatar. Immunity, Inflammation and Disease. 2025. doi:10.1002/iid3.70195

BibTeX
@article{Sasi2025,
  author = {Sasi, Sreethish and Hadi, Hamad Abdel and Chaponda, Masautso and El Ajez, Reem and Ataelmanan, Mohamed and Khasawneh, Sief and Saqallah, Hind and Ali, Maisa and Abdulla, Nabeel and Iqbal, Javed and Omrani, Ali S and Al Maslamani, Muna and Al-Khal, Abdullatif},
  title = {Risk of Serious Infections in Patients Treated With Biologic or Targeted‐synthetic Disease Modifying Antirheumatic Drugs in Qatar},
  journal = {Immunity, Inflammation and Disease},
  year = {2025},
  doi = {10.1002/iid3.70195}
}
Kostenlos starten →